RAPT Therapeutics, Inc. (RAPT) Cash & Equivalents (2020 - 2024)
RAPT Therapeutics (RAPT) has disclosed Cash & Equivalents for 5 consecutive years, with $37.9 million as the latest value for Q3 2024.
- Quarterly Cash & Equivalents fell 29.99% to $37.9 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $37.9 million through Sep 2024, down 29.99% year-over-year, with the annual reading at $47.4 million for FY2023, 21.69% up from the prior year.
- Cash & Equivalents hit $37.9 million in Q3 2024 for RAPT Therapeutics, up from $37.1 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $91.5 million in Q1 2020 to a low of $20.2 million in Q3 2020.
- Historically, Cash & Equivalents has averaged $43.9 million across 5 years, with a median of $38.9 million in 2022.
- Biggest YoY gain for Cash & Equivalents was 197.75% in 2021; the steepest drop was 72.99% in 2021.
- Year by year, Cash & Equivalents stood at $24.9 million in 2020, then decreased by 3.58% to $24.0 million in 2021, then surged by 62.09% to $38.9 million in 2022, then increased by 21.69% to $47.4 million in 2023, then fell by 20.03% to $37.9 million in 2024.
- Business Quant data shows Cash & Equivalents for RAPT at $37.9 million in Q3 2024, $37.1 million in Q2 2024, and $45.3 million in Q1 2024.